Cambridge, United States
FogPharma, founded in 2016 and headquartered in the United States, is at the forefront of revolutionizing drug development. Operating within the Biopharma, Biotechnology, Health Care, Life Sciences, and Pharmaceutical industries, their slogan, "Until everything is druggable," encapsulates their ambitious mission.
The company specializes in creating a novel class of drugs known as HeliconTM peptides, which uniquely merge the efficacy of monoclonal antibodies with the cell-penetrating efficiency of small molecules. This innovation holds the potential to effectively target a wide array of human disease drivers with unprecedented speed and scalability.
In March 2024, FogPharma secured a substantial $145.00M Series E investment, reflecting strong investor confidence. Key investors include RA Capital Management, Marshall Wace, T. Rowe Price, 60 Degree Capital, Milky Way Ventures, Nextech Invest, Rock Springs Capital, Samsara BioCapital, VenBio Partners, and SymBiosis. This funding will propel their groundbreaking therapeutic developments.
Cybrexa Therapeutics
